Т.П. Пронько, В.А. Снежицкий, В.Р. Шулика
УО «Гродненский государственный медицинский университет»
Цель исследования. Провести анализ маркеров, влияющих на развитие лабораторной резистентности к ацетилсалициловой кислоте (АСК) у пациентов со стабильной стенокардией напряжения.
ключевые слова: аспиринорезистентность, стабильная стенокардия напряжения, агрегация тромбоцитов, воспаление, дисфункция эндотелия

для цитирования: Т.П. Пронько, В.А. Снежицкий, В.Р. Шулика. Результаты факторного анализа маркеров лабораторной резистентности к ацетилсалициловой кислоте у пациентов со стабильной стенокардией напряжения. Неотложная кардиология и кардиооваскулярные риски, 2019, Т. 3, № 2, С. 713–718

Results of factor analysis of laboratory resistance markers to acetylsalicylic acid in patients with stable angina
T.P. Pronko, V.A. Snezhitskiy, V.R. Shulika
The aim of the study was to assess the markers influencing the development of acetylsalicylic acid (ASA) laboratory resistance in patients with stable angina.
keywords: aspirin resistance, stable angina, platelet aggregation, inflammation, endothelial dysfunction

for references: T.P. Pronko, V.A. Snezhitskiy, V.R. Shulika. Results of factor analysis of laboratory resistance markers to acetylsalicylic acid in patients with stable angina. Neotlozhnaya kardiologiya i kardioovaskulyarnye riski [Emergency cardiology and cardiovascular risks], 2019, vol. 3, no. 2, pp. 713–718

1. Michelson A.D., Cattaneo M., Eikelboom J.W. ., Gurbel P., Kottke-Marchant K., Kunicki T.J., Pulcinelli F.M., Cerletti C., Rao A.K. Aspirin Resistance: Position Paper of the Working Group on Aspirin Resistance, Platelet Physiology Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. J. Thromb Haemost, 2005, vol. 3, no. 6, pp. 1309–1311.
2. Snoep J.D., Hovens M.M., Eikenboom J.C., van der Bom J.G. Huisman M.V. Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and metaanalysis. Arch Intern Med, 2007, vol. 167, no. 15, pp. 1593–1599.
3. Puchin’yan N.F., Furman N.V., Dolotovskaya P.V., Malinova L.I. Vy’sokaya ostatochnaya reaktivnost’ trombocitov na fone dvoynoy antiagregantnoy terapii, vy’yavlennaya metodom opticheskoy agregometrii, i chastota razvitiya aterotromboticheskih oslojneniy posle stentirovaniya koronarny’h arteriy u bol’ny’h ishemicheskoy bolezn’yu serdca v real’noy klinicheskoy praktike [High residual platelet reactivity during dual antiplatelet therapy, detected by optical aggregometry, and the incidence of atherothrombotic complications after stenting of coronary arteries in patients with coronary heart disease in real clinical practice]. Ratsional’nya farmakoterapiya v kardiologii, 2016, vol. 12, no. 4, pp. 385–390. (in Russian).
4. Pronko T.P., Snezhitskiy V.A., Makarova E.A, Avseenko A.A., Kharitonenko Т.V. Osobennosti trombocitarnogo gemostaza u pacientov s razlichnoj chuvstvitel’nost’yu k antitrombocitarnoj terapii pri stabil’noj stenokardii napryazheniya posle planovogo chreskozhnogo koronarnogo vmeshatel’stva [Features of platelet hemostasis in patients with various sensitivity to antiplatelet therapy in patients with angina pectoris in planned percutaneous coronary intervention]. Zhurnal Grodnenskogo gosudarstvennogo meditsinskogo universiteta, 2017, vol. 15, no 5, pp. 503–508. (in Russian).
5. Wisman P.P., Roest M., Asselbergs F.W., de Groot P.G., Moll F.L., van der Graaf Y., de Borst G.J. Platelet-reactivity tests identify patients at risk of secondary cardiovascular events: a systematic review and meta-analysis. J. Thromb. Haemost, 2014, vol. 12, no. 5, pp. 736–747.
6. Kukula K., Klopotowski M., Kunicki P., Jamiolkowski J., Debski A., Bekta P., Chmielak Z., Witkowski A. Platelet aggregation and the risk of stent thrombosis or bleeding in elective percutaneous coronary intervention patients. Blood Coagul Fibrinolysis, 2017, vol. 28, no. 5, pp. 383–388. doi: 10.1097/MBC.0000000000000614.
7. Würtz M. Aspirin in coronary artery disease: an appraisal of functions and limitations. Dan. Med. J, 2015, vol. 62, no. 4, pp. B5011.
8. Gremmel T., Michelson A.D., Frelinger A.L., Bhatt D.L. Novel aspects of antiplatelet therapy in cardiovascular disease. Res. Pract. Thromb. Haemost, 2018, vol. 2, no. 3, pp. 439–449. doi: 10.1002/rth2.12115. eCollection 2018 Jul.
9. Martynov A.I., Akatova E.V., Urlayeva I.V., Nicolin O.P. True resistance and pseudoresistance to aspirin. Ration Pharmacother Cardiol, 2013, vol. 9, no 3, pp. 301–305.
10. Lomakin N.V., Sumarokov A.B., Dotsenko Yu.V., Uchitel I.A., Buryachkovskaya L.I. Individual approach to patients with indication for antiplatelet therapy. What to rely on in choosing the therapy? [Individual approach to patients with indication for antiplatelet therapy. What to rely on in choosing the therapy?]. Aterotromboz, 2017, no. 2, pp. 70–80. (in Russian).
11. Calatzis A., Loreth R., Spannagl M. Multiplate® platelet function analysis - application and interpretation [electronic resource]. Available at: ttp://www.ecomeds.ru/data/files/catalog/1.%20Compendium%20Multiplate%20final%20V2.0_07.2007.pdf. (accessed 24.10.2019).
12. Bobescu E., Covaciu A., Rus H., Radoi M., Badea M., Moga S.N., Benza V, Marceanu L.G. Correlation of cardiovascular risk factors and biomarkers with platelet reactivity in coronary artery disease. Am. J. Ther, 2019, vol. 26, no. 5, pp. 563–569. doi: 10.1097/MJT.0000000000000869.
13. Larsen S.B., Grove E.L., Neergaard-Petersen S., Würtz M., Hvas A.M., Kristensen S.D. Determinants of reduced antiplatelet effect of aspirin in patients with stable coronary artery disease. PLoS One, 2015, vol. 10, no. 5, pp.e0126767. doi: 10.1371/journal.pone.0126767. eCollection 2015.
14. Winter M.P., Schneeweiss T., Cremer R., Biesinger B., Hengstenberg C., Prüller F., Wallner M., Kolesnik E., von Lewinski D., Lang I.M., Siller-Matula J.M. Platelet reactivity patterns in patients treated with dual antiplatelet therapy. Eur J Clin Invest, 2019, vol. 49, no. 6, pp.e13102. doi: 10.1111/eci.13102.
15. Gelis L.G., Markova I.A., Medvedeva E.A., Shibeko N.A. Diagnosticheskaja rol trombocitov i plazmennyh faktorov krovi v razvitii aterotromboza [Diagnostic role of platelets and plasma blood factors in the development of atherothrombosis]. Kardiologija v Belarusi, 2012, no. 2, pp. 123–134. (in Russian).
16. Barinov Je. F., Gnilorybov A.M., Sulaeva O.N., Kanana N.N., Gatina E.I. Funkcionalnoe sostojanie trombocitov pri ishemicheskoj bolezni serdca [Functional state of thrombocytes in ischemic heart disease]. Vestnik neotlozhnoj i vosstanovitelnoj mediciny, 2013, vol. 14, no. 2, pp. 278–282. (in Russian).
17. Mazurov A.V. Oborot trombocitov i aterotromboz [The turnover of platelets, and atherothrombosis]. Aterotromboz, 2017, no. 2, pp. 131–141. (in Russian).
18. Sansanayudh N., Anothaisintawee T., Muntham D., McEvoy M., Attia J., Thakkinstian A. Mean platelet volume and coronary artery disease: a systematic review and meta-analysis. Int. J. Cardiol, 2014, vol. 175, no. 3, pp. 433–440. doi: 10.1016/j.ijcard.2014.06.028.
19. Chu S.G., Becker R.C., Berger P.B., Bhatt D.L., Eikelboom J.W., Konkle B., Mohler E.R., Reilly M.P., Berger J.S. Mean platelet volume as a predictor of cardiovascular risk: a systematic review and meta-analysis. J. Thromb. Haemost, 2010, vol. 8, no. 1, pp. 148–156.
20. Gromov A.A., Kruchinina M.V., Shvarts YA.SH., Kruchinin V.N., Rykhlitskiy S.V. Sistema gemostaza i aterogenez [Hemostasis system and atherogenesis]. Ateroskleroz, 2016, vol. 12, no. 2, pp. 39–60. (in Russian).
21. Kruchinina M.V., Gromov A.A., Rabko A.V., Abdullayeva P.A., Baum V.A., Generalov V.M., Generalov K.V., Kruchinin V.N., Rykhlitskiy S.V., Shuvalov G.V. Aspirinorezis-tentnost’ kak marker riska venoznykh tromboembolicheskikh oslozhneniy [Aspirin resistance as a marker of risk of venous thromboembolic complications]. Ateroskleroz, 2018, vol. 14, no. 4, pp. 40–54. (in Russian).
22. Gimbrone M.A. Jr, García-Cardeña G. Endothelial Cell Dysfunction and the Pathobiology of Atherosclerosis. Circ. Res, 2016, vol. 118, no. 4, pp. 620–636. doi: 10.1161/CIRCRESAHA.115.306301.
23. Rajendran S., Chirkov Y.Y. Platelet hyperaggregability: impaired responsiveness to nitric oxide (“platelet NO resistance”) as a therapeutic target. Cardiovasc Drugs Ther, 2008, vol. 22, no. 3, pp. 193–203. doi: 10.1007/s10557-008-6098-7.
24. Verigo YA.I., Demko I.V., Petrova M.M., Sobko Ye.A., Mamayeva M.G. Faktor Villenbranda i yego rol’ v disfunktsii endoteliya pri ishemicheskoy bolezni serdtsa [Willenbrand factor and its role in endothelial dysfunction in coronary heart disease]. Sibirskoye meditsinskoye obozreniye, 2014, no. 5, pp. 23–28. (in Russian).
25. Sokolov Ye.I., GrishinaT.I., Shtin S.R. Vliyaniye faktora Villebranda i endotelina-1 na formirovaniye tromboticheskogo statusa pri ishemicheskoy bolezni serdtsa [The effect of von Willebrand factor and endothelin-1 on the formation of thrombotic status in coronary heart disease]. Kardiologiya, 2013, no. 3, pp. 25–30. (in Russian).
Формат файла: pdf (493.36 Кб)